Page 2 - Cardio_11_2021
P. 2

POWER




           MEETS






           SYNERGY





           Synjardy® INDICATED to improve
           glycemic control and reduce the risk of
           cardiovascular death in adults with T2D
           & established cardiovascular diseases     1










           Available as:
           5mg/500mg, 5mg/850mg, 5mg/1000mg,
           12.5mg/500mg, 12.5mg/850mg,
           12.5mg/1000mg



















                         RRR
                Relative risk reduction in CV death -                     HbA1c REDUCTION
              Results from EMPA REG OUTCOME® trial 1,2
                                                                           Synjardy® effectively lowers HbA1c up to 4.6% 3
            Absolute Risk Reduction 2.2%






                                                                                             ®
                                                                                     Jardiance  recommended
               80               Guideline Recommendations                           to reduce the risk of Cardiovascular
                                                                                           by SEMDSA
                                More than 80 standard guidelines across
                                the globe has incorporated evidence from           death in Type 2 Diabetes patients with
                                                                                    established cardiovascular disease.
                                EMPA-REG outcome. 4

         References: 1.  Synjardy  approved prescribing information, Boehringer Ingelheim 2020.  2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME  Investigators. Empagliflozin,
                                                                                                ®
                       ®
         cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. 3. Hadjadj S, et al. Diabetes Care 2016; 2016 Oct;39(10):1718-28. doi: 10.2337/dc16-0522.
         4. Boehringer Ingelheim data on file.
                                Synjardy  is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve
                                     ®
                                glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in patients inadequately
                                controlled with metformin in combination with other glucose-lowering medicine.
                                For full prescribing information refer to the professional information approved by the Regulatory Authority. Applicant details: Ingelheim Pharmaceuticals (Pty)
                                Ltd, 407 Pine Ave, Randburg. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-101048. Expiry date: March 2023.
   1   2   3   4   5   6   7